APG 333
Alternative Names: APG-333; PR-018Latest Information Update: 19 Nov 2025
At a glance
- Originator Apogee Therapeutics
- Class Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Asthma
Most Recent Events
- 10 Nov 2025 Pharmacodynamics, pharmacokinetics and adverse events data from phase-I trial in Asthma (In volunteers) released by Apogee Therapeutics
- 17 May 2025 Pharmacodynamics data from a preclinical Trial in Asthma presented at the 121st International Conference of the American Thoracic Society (ATS-2025)
- 28 Feb 2025 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Asthma presented at the 2025 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2025)